Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUMEX vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Edema associated with congestive heart failure,Edema associated with hepatic cirrhosis,Edema associated with renal disease including nephrotic syndrome
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (Cr Cl <20 m L/min).
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
Bumetanide is 94–96% bound to plasma proteins (primarily albumin).
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
0.15–0.22 L/kg; indicates primarily extracellular distribution.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral bioavailability: 80–100% (mean ~95%).
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
e GFR <20 m L/min/1.73 m²: Avoid loop diuretics; consider alternative. No adjustment for mild to moderate renal impairment, but monitor response. In severe renal failure, may require higher doses due to reduced tubular secretion.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Child-Pugh Class B or C: Reduce initial dose by 50% due to impaired metabolism and increased risk of volume depletion. Titrate cautiously.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Infants/Children: Oral: 0.015-0.1 mg/kg/dose once daily; maximum 10 mg/day. IV/IM: 0.015-0.1 mg/kg/dose every 12-24 hours; maximum 0.5 mg/kg/dose. Neonates: 0.01-0.05 mg/kg/dose every 24-48 hours.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Start at 0.5 mg orally once daily; increase cautiously due to enhanced pharmacodynamic effects and higher risk of electrolyte disturbances, volume depletion, and ototoxicity. Monitor renal function and electrolytes closely.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Bumetanide is a potent diuretic; if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule must be adjusted to individual patient's needs.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypovolemia,Ototoxicity (especially with rapid injection or in renal impairment),Excessive diuresis causing hypotension and thromboembolic events,May increase serum uric acid levels and precipitate gout,Risk of hypokalemia in patients with cirrhosis and ascites
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Anuria,Hepatic coma or severe electrolyte depletion until condition is corrected,Hypersensitivity to bumetanide or sulfonamides (cross-sensitivity possible)
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Avoid excessive salt intake; no specific food interactions reported. Avoid licorice as it may worsen hypokalemia. Grapefruit juice may increase bumetanide levels; use caution.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are limited; no well-controlled studies exist. First trimester: theoretical risk based on animal data; avoid unless essential. Second/third trimesters: may cause maternal hypovolemia, decreased placental perfusion, and fetal oliguria; use only if clearly needed and monitor amniotic fluid volume. Neonatal risks include electrolyte imbalances and ototoxicity if used close to delivery.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Bumetanide is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05-0.10. Based on limited data, amounts ingested by breastfed infants are unlikely to cause adverse effects. However, due to potential risk of hypersensitivity, electrolyte disturbances, or diuresis in the infant, caution is advised, especially in premature or renal-impaired infants. Alternative diuretics with more safety data may be preferred.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
Pregnancy may alter bumetanide pharmacokinetics due to increased plasma volume, renal blood flow, and glomerular filtration rate. Higher doses may be required to achieve the same diuretic effect. However, no standard dose adjustment guidelines exist; use the lowest effective dose and titrate based on clinical response, monitoring for electrolyte disturbances and volume depletion. In severe preeclampsia or renal impairment, dose may need reduction. Close therapeutic drug monitoring is not routinely available; clinical monitoring of diuresis and electrolytes guides dosing.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Bumetanide is a loop diuretic approximately 40 times more potent than furosemide; onset of diuresis within 30-60 minutes after oral administration. Monitor for ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Hypokalemia is a common adverse effect; consider potassium supplementation or concurrent use of potassium-sparing diuretics. Contraindicated in anuria, hepatic coma, and severe electrolyte depletion. May cause hyperuricemia and precipitate gout attacks.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Take this medication exactly as prescribed, typically once daily in the morning to avoid nighttime urination.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Do not consume grapefruit juice or alcohol while taking this drug.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or confusion.,Weigh yourself daily and report rapid weight gain or loss to your healthcare provider.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
No interactions on record
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUMEX vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
BUMEX is a Loop Diuretic that works by Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUMEX and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUMEX is: 0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUMEX and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUMEX is classified as Category C. Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are l. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.